Anders Tullgren
Anders has over 35 years of global experience in the pharmaceutical industry and has had senior leadership roles in the United States, Germany, France, the United Kingdom and the Nordic region. The latest role he left in 2017 was as President of the Intercontinental region of Bristol Myers Squibb with responsibility for over 30 countries, 5,000 employees and a turnover of over 20 billion SEK. He is chairman of the board of BerGenBio, Norway and Farmalisto, Colombia. Anders is board member of Branding Science Ltd, UK and member of the Business Development and Launch Committee of the Board of Directors for Norgine. He holds a MSc in Pharmacy from Uppsala University.
Chairman of the Board since 2018
Shares: 20,564
Independent in relation to the company and company management and major shareholders
Eva Nilsagård
Eva Nilsagård holds a Executive MBA in Economics and a Bsc in accounting and finance from School of Business, Economics and Law in Gothenburg. Eva is the founder and CEO of Nilsagård Consulting AB which offers assignments as CEO and CFO. Previously, Eva has, among other things, served as CFO of Plastal Industry and Vitrolife, Senior Vice President Strategy & Business Development at Volvo Group and held senior positions in finance and business development in, for example, Volvo, AstraZeneca and SKF. Eva is a board member and chairman of the audit committee of Addlife, Bufab and Irras and board member of SEK (Swedish Export Credit Company). Eva has more than ten years of experience as a mentor for young female managers with high potential.
Board member since 2019
Shares: 1,632
Independent in relation to the company and company management and major shareholders
Mats Thorén
Mats has studied economics and business economics at Stockholm School of Economics, as well as studies in medicine at Karolinska Institutet in Stockholm. He has over 20 years of experience in the financial market where he has worked primarily in the Life Science sector both as an analyst and in Corporate Finance. For 12 years, Mats has been a professional investor and manages its own company, Vixco Capital, with a focus on investments. Mats has previous board experience from C-Rad AB, Cellartis AB and MIP Technologies AB. Mats is currently a board member of Arcoma Aktiebolag and Arcoma Incentive AB, board member and CEO of Vixco Capital AB and deputy board member of Eggelbertus Holding AB and board member of Herantis Pharma Oy.
Board member since 2020
Shares: 34,501
Independent in relation to the company and company management and major shareholders
Kirsti Gjellan
Kirsti holds a Master of Science and a Ph.D. in Pharmaceutical technology from the University of Oslo and more than 30 years of experience from the International Life Science and Pharmaceutical industries. With roles such as Managing Director for Pfizer Health AB and, Global head of manufacturing, quality operations, biologics process development and supply at Swedish Orphan Biovitrum AB (Sobi). She has previously held leading positions at AstraZeneca, Pfizer and Sobi. Current assignments as Board Executive of Bio-Works Sweden AB and, Envirotainer Holding AB. Previous board assignments at Vinnova funded PiiA, SwedenBio, OxThera AB and, Pfizer Health AB.
Board member since 2022
Shares: 1,020
Independent in relation to the company and company management and major shareholders
Kristoffer Bissessar
Current assignment: Board member, chair of the audit comittee and member of the remuneration committee in BioInvent International Aktiebolag.
Previous assignments: Board member and managing director in Evolvere Partners AB.
Board member since 2024
Shares: 16,000
Independent in relation to the company and company management and major shareholders